Evidence map›Paper›PMID 27418955›Full record

ArticleComputational and structural biotechnology journal2016

Application of the Protein Maker as a platform purification system for therapeutic antibody research and development.

Geneviève Hélie, Marie Parat, Frédéric Massé, Cory J Gerdts, Thomas P Loisel, Allan Matte

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Geneviève HélieProtein Purification, Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave. Montreal, QC H4P 2R2, Canada.
Marie ParatProtein Purification, Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave. Montreal, QC H4P 2R2, Canada.
Frédéric MasséPrimary Assays, Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave. Montreal, QC H4P 2R2, Canada.
Cory J GerdtsProtein BioSolutions Inc., Suite 280, 401 Professional Drive, Gaithersburg, MD, 20879, USA.
Thomas P LoiselProtein Purification, Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave. Montreal, QC H4P 2R2, Canada.
Allan MatteProtein Purification, Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave. Montreal, QC H4P 2R2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within the research and development environment, higher throughput, parallelized protein purification is required for numerous activities, from small scale purification of monoclonal antibodies (mAbs) and antibody fragments for in vitro and in vivo assays to process development and optimization for manufacturing. Here, we describe specific applications and associated workflows of the Protein Maker liquid handling system utilized in both of these contexts. To meet the requirements for various in vitro assays, for the identification and validation of new therapeutic targets, small quantities of large numbers of purified antibodies or antibody fragments are often required. Reducing host cell proteins (HCP) levels following capture with Protein A by evaluating various wash buffers is an example of how parallelized protein purification can be leveraged to improve a process development outcome. Stability testing under various conditions of in-process intermediates, as an example, the mAb product from a clarified harvest, requires parallelized protein purification to generate concurrent samples for downstream assays. We have found that the Protein Maker can be successfully utilized for small-to-mid scale platform purification or for process development applications to generate the necessary purified protein samples. The ability to purify and buffer exchange up to 24 samples in parallel offers a significant reduction in time and cost per sample compared to serial purification using a traditional FPLC system. By combining the Protein Maker purification system with a TECAN Freedom EVO liquid handler for automated buffer exchange we have created a new, integrated platform for a variety of protein purification and process development applications.

Indexed as

AntibodyCHO, Chinese Hamster OvaryDPBS, Dulbecco's phosphate buffered salineHC, IgG heavy chainHCP, host cell proteinHybridomaIMAC, immobilized metal ion affinity chromatographyLC, IgG light chainmAb, monoclonal antibodyOAA, one-armed antibodyParallelized protein purificationProcess developmentProtein AProtein G

Identifiers

PMID27418955
PMCPMC4932438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.